- Home
- PCRX vs DGNX Comparison
PCRX vs DGNX Comparison
Compare PCRX & DGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- DGNX
- Stock Information
- Founded
- PCRX 2006
- DGNX 2018
- Country
- PCRX United States
- DGNX United Kingdom
- Employees
- PCRX N/A
- DGNX N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- DGNX
- Sector
- PCRX Health Care
- DGNX
- Exchange
- PCRX Nasdaq
- DGNX NYSE
- Market Cap
- PCRX 1.2B
- DGNX 1.2B
- IPO Year
- PCRX 2011
- DGNX 2025
- Fundamental
- Price
- PCRX $24.10
- DGNX $45.00
- Analyst Decision
- PCRX Buy
- DGNX
- Analyst Count
- PCRX 9
- DGNX 0
- Target Price
- PCRX $29.89
- DGNX N/A
- AVG Volume (30 Days)
- PCRX 546.7K
- DGNX 54.9K
- Earning Date
- PCRX 07-29-2025
- DGNX 01-01-0001
- Dividend Yield
- PCRX N/A
- DGNX N/A
- EPS Growth
- PCRX N/A
- DGNX N/A
- EPS
- PCRX N/A
- DGNX N/A
- Revenue
- PCRX $702,772,000.00
- DGNX $1,177,066.00
- Revenue This Year
- PCRX $7.54
- DGNX N/A
- Revenue Next Year
- PCRX $10.78
- DGNX N/A
- P/E Ratio
- PCRX N/A
- DGNX N/A
- Revenue Growth
- PCRX 3.08
- DGNX N/A
- 52 Week Low
- PCRX $11.16
- DGNX $3.60
- 52 Week High
- PCRX $29.61
- DGNX $155.00
- Technical
- Relative Strength Index (RSI)
- PCRX 36.99
- DGNX N/A
- Support Level
- PCRX $23.99
- DGNX N/A
- Resistance Level
- PCRX $24.90
- DGNX N/A
- Average True Range (ATR)
- PCRX 0.88
- DGNX 0.00
- MACD
- PCRX -0.21
- DGNX 0.00
- Stochastic Oscillator
- PCRX 11.61
- DGNX 0.00
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About DGNX DIGINEX LIMITED
Diginex Ltd is an investment holding company. It engaged in providing Environmental, Social, and Governance (ESG) reporting solution services, advisory services, and developing customization solutions.